Abstract

It is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect human kidney, thus leading to acute kidney injury (AKI). Here, we perform a retrospective analysis of clinical parameters from 85 patients with laboratory-confirmed coronavirus disease 2019 (COVID-19); moreover, kidney histopathology from six additional COVID-19 patients with post-mortem examinations was performed. We find that 27% (23/85) of patients exhibited AKI. The elderly patients and cases with comorbidities (hypertension and heart failure) are more prone to develop AKI. Haematoxylin & eosin staining shows that the kidneys from COVID-19 autopsies have moderate to severe tubular damage. In situ hybridization assays illustrate that viral RNA accumulates in tubules. Immunohistochemistry shows nucleocapsid and spike protein deposits in the tubules, and immunofluorescence double staining shows that both antigens are restricted to the angiotensin converting enzyme-II-positive tubules. SARS-CoV-2 infection triggers the expression of hypoxic damage-associated molecules, including DP2 and prostaglandin D synthase in infected tubules. Moreover, it enhances CD68+ macrophages infiltration into the tubulointerstitium, and complement C5b-9 deposition on tubules is also observed. These results suggest that SARS-CoV-2 directly infects human kidney to mediate tubular pathogenesis and AKI.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to acute kidney injury. The authors describe that SARS-COV-2 can directly infect human kidney, possibly mediating tubular pathogenesis.

Details

Title
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection
Author
Diao, Bo 1 ; Wang, Chenhui 2 ; Wang Rongshuai 3 ; Feng Zeqing 2 ; Zhang, Ji 2 ; Yang, Han 2 ; Tan Yingjun 4 ; Wang, Huiming 5 ; Wang Changsong 6 ; Liu, Liang 7 ; Liu, Ying 4 ; Liu, Yueping 4 ; Wang, Gang 4 ; Yuan Zilin 4 ; Hou Xiaotao 8 ; Ren, Liang 3 ; Wu Yuzhang 2   VIAFID ORCID Logo  ; Chen Yongwen 2   VIAFID ORCID Logo 

 Third Military Medical University, Institute of Immunology, PLA, Chongqing, P. R. China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682); Department of Medical Laboratory Center, General Hospital of Central Theater Command, Wuhan, P. R. China (GRID:grid.417279.e); Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan, P. R. China (GRID:grid.417279.e) 
 Third Military Medical University, Institute of Immunology, PLA, Chongqing, P. R. China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682) 
 Huazhong University of Science and Technology, Department of Forensic Medicine, Tongji Medical College, Wuhan, P. R. China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223) 
 Department of Medical Laboratory Center, General Hospital of Central Theater Command, Wuhan, P. R. China (GRID:grid.417279.e) 
 Renmin Hospital of Wuhan University, Department of Nephrology, Wuhan, P. R. China (GRID:grid.412632.0) (ISNI:0000 0004 1758 2270) 
 989th Hospital of PLA, Department of Pathology, Luoyang, P. R. China (GRID:grid.412632.0) 
 Hubei Chongxin Judicial Expertise Center, Wuhan, P. R. China (GRID:grid.412632.0) 
 Guangzhou KingMed Center for Clinical Laboratory Co., Ltd., Guangzhou, P. R. China (GRID:grid.417279.e) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2521814432
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.